Key result
Once-daily high-dose edoxaban significantly reduced major bleeding compared with rivaroxaban (RR 0.76; 95% CI 0.66-0.89) and dabigatran, with similar efficacy for stroke prevention.
Why the study?
Does edoxaban reduce major bleeding or stroke and systemic embolism compared to other nonvitamin K antagonist oral anticoagulants in patients with nonvalvular atrial fibrillation and CHADS2 score ⩾ 2?
Meta-Analysis
Does edoxaban reduce major bleeding or stroke and systemic embolism compared to other nonvitamin K antagonist oral anticoagulants in patients with nonvalvular atrial fibrillation and CHADS2 score ⩾ 2?
Relative Risk: 0.76 (95% CI 0.66–0.89)
In patients with AF and CHADS2 score ⩾ 2, high-dose edoxaban provides similar stroke prevention efficacy as other NOACs but with a significantly lower risk of major bleeding compared to rivaroxaban and dabigatran.
No takes yet. Share an insight, caveat, or question.
Provides adjusted indirect comparisons of edoxaban versus other NOACs in AF; extends pivotal trial evidence by accounting for baseline risk and follow-up differences.
Fernandez et al. (2015) conducted a meta-analysis in Nonvalvular atrial fibrillation. Edoxaban vs. Other nonvitamin K antagonist oral anticoagulants (rivaroxaban, dabigatran, apixaban) and warfarin was evaluated on Major bleeding episodes (RR 0.76, 95% CI 0.66-0.89). Once-daily high-dose edoxaban significantly reduced major bleeding compared with rivaroxaban (RR 0.76; 95% CI 0.66-0.89) and dabigatran, with similar efficacy for stroke prevention.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: